EZH2 and neoplasm: Thus, the substantially reduced tumor growth seen in the mice treated with Taz plus B32B3 compared to the mice treated with Taz or B32B3 alone indicates that Taz in the combination treatment impaired the residual tumorigenic activities of EZH2 in the xenograft tumors.